ArticleTranslational andrology and urology2021

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.

Elliot Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.